EUVIMEDOpdag EUVIMED
Open access · CC BY-NC 4.0

Peanut Component‐Specific IgE and IgG4 Are Modulated by Sublingual Immunotherapy and Are Associated With Remission in 1–4‐Year‐Old Children

Neel Singh iD, Janelle Kesselring iD, Jess Humphrey iD, Lauren Herlihy iD, A Wesley Burks iD, Johanna Smeekens iD, Corinne Keet iD, J Andrew Bird iD, Edwin H Kim iD, Michael Kulis iD

Allergy · 2026

DOI: 10.1111/all.70111 ↗

At a glance

Journal article in Allergy, 2026. Written by Neel Singh and 9 co-authors. Institution: Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA. Major MEDLINE topics: Immunoglobulin G, Immunoglobulin E, Peanut Hypersensitivity, Sublingual Immunotherapy. Cited 7 times so far (Crossref); 35 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: NIH HHS, Food Allergy Research and Education, NCCIH NIH HHS.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

The safety and efficacy of 36‐month peanut sublingual immunotherapy (SLIT) was recently demonstrated in peanut‐allergic children (1–4 years old), with high remission rates three months post‐treatment.

Methods

We performed a post hoc analysis of longitudinal changes in peanut component‐specific IgE (PnC‐sIgE) and IgG4 (PnC‐sIgG4) levels in 1–4 year olds who underwent peanut SLIT to uncover immune mechanisms and potential biomarkers of remission. Plasma from 30 participants was analyzed at 0, 12, 24, 36, and 39 months using ImmunoCAP250 for PnC‐sIgE and PnC‐sIgG4 to Ara h 1, Ara h 2, Ara h 3, and Ara h 6 (Ah1‐6). Mixed‐effects models assessed longitudinal antibody changes, Wilcoxon tests compared antibody levels by remission status, and correlations evaluated age and baseline antibody levels.

Results

Peanut SLIT reduced IgE levels while increasing IgG4 levels specific to Pn and Ah1‐6 over 36 months. No changes in sIgE were observed in the placebo group, whereas increases in Pn‐, Ah1‐, and Ah3‐sIgG4 were noted. Participants achieving remission had lower IgE and IgG4 to Pn and Ah1‐6 at baseline and throughout 36 months of SLIT. Ah2‐sIgG4 showed no overlap between outcome groups at baseline, suggesting potential as a biomarker. Children under 3 had lower baseline Ah6‐sIgE and Ah1‐, Ah2‐, and Ah6‐sIgG4 levels and higher remission rates than those 3 and older, linking age, remission, and antibody profiles.

Conclusion

Component‐resolved analysis offers key insights into the immunological mechanisms in young children undergoing peanut SLIT, revealing lower baseline levels of Ah2‐sIgG4 as a potential biomarker of remission.

Subjects

MeSH terms (MEDLINE)

Immunoglobulin GImmunoglobulin EPeanut HypersensitivitySublingual ImmunotherapyArachisAllergensHumansChild, PreschoolFemaleMaleInfantTreatment OutcomeBiomarkersRemission InductionAntibody Specificity

Author keywords

SLITdesensitizationpeanut allergyremissionsublingual immunotherapy

Substances

Immunoglobulin GImmunoglobulin EBiomarkersAllergens

Authors and institutions

  • Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
  • Department of Nutrition, University of North Carolina Gillings School of Global Public Health, Chapel Hill, North Carolina, USA.
  • Curriculum in Toxicology and Environmental Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
  • Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

ORCID profiles: Neel Singh, Janelle Kesselring, Jess Humphrey, Lauren Herlihy, A Wesley Burks, Johanna Smeekens, Corinne Keet, J Andrew Bird, Edwin H Kim, Michael Kulis

Funding

  • NIH HHS
  • Food Allergy Research and Education
  • NCCIH NIH HHS
  • University of North Carolina at Chapel Hill
  • Meade Family Pediatric Allergy Research Fund
  • NCATS NIH HHS
  • National Institutes of Health
  • National Center for Complementary and Integrative Health

Cite

APA

Singh, N., Kesselring, J., Humphrey, J., Herlihy, L., Burks, A. W., Smeekens, J., Keet, C., Bird, J. A., Kim, E. H., & Kulis, M. (2026). Peanut Component‐Specific IgE and IgG4 Are Modulated by Sublingual Immunotherapy and Are Associated With Remission in 1–4‐Year‐Old Children. Allergy. https://doi.org/10.1111/all.70111

Vancouver

Singh N, Kesselring J, Humphrey J, Herlihy L, Burks AW, Smeekens J, et al. Peanut Component‐Specific IgE and IgG4 Are Modulated by Sublingual Immunotherapy and Are Associated With Remission in 1–4‐Year‐Old Children. Allergy. 2026. doi:10.1111/all.70111

BibTeX
@article{Singh2026,
  author = {Singh, Neel and Kesselring, Janelle and Humphrey, Jess and Herlihy, Lauren and Burks, A Wesley and Smeekens, Johanna and Keet, Corinne and Bird, J Andrew and Kim, Edwin H and Kulis, Michael},
  title = {Peanut Component‐Specific IgE and IgG4 Are Modulated by Sublingual Immunotherapy and Are Associated With Remission in 1–4‐Year‐Old Children},
  journal = {Allergy},
  year = {2026},
  doi = {10.1111/all.70111}
}
Start for free →